PDCD1 and neoplasm: Compared with anti-PD-1 or vvDD-IL-15R-α monotherapy, vvDDIL-15R-α combined with the PD-1 antibody induced significant tumor regression and prolonged the survival of colon or ovarian cancer mice [112].